Added to YB: 2025-01-17
Pitch date: 2025-01-15
KROS [bullish]
Keros Therapeutics, Inc.
+102.73%
current return
Author Info
Clark Street Value is a special sits/event-driven investor. Sign up for the newsletter.
Company Info
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States.
Market Cap
$525.8M
Pitch Price
$10.61
Price Target
16.05 (-25%)
Dividend
N/A
EV/EBITDA
-2.82
P/E
10.96
EV/Sales
-0.61
Sector
Biotechnology
Category
special_situation
Keros Therapeutics: Pre-SA Broken Biotech, Large Cash Position
KROS: Pre-SA broken biotech. Phase 2 KER-012 halted due to pericardial effusions. $650M cash for reverse merger. KER-050 out-licensed to Takeda for $200M + milestones. No strategic review yet. Est. NAV $18.73/share. Potential upside from Takeda deal milestones not included in NAV.
Read full article (2 min)